1,877 cancer cases detected in Tiruchy in last 4 years
Extending the programme, health minister M Subramaniam on Monday inaugurated state-wide Organised Cancer Screening (OCS) camps at Tiruvallur and 12 other districts. In Tiruchy, collector M Pradeep Kumar inaugurated the camp at a wellness centre in Woraiyur.
This is part of Tamil Nadu's Rs 27-crore cancer control strategy, and the drive focuses on detecting oral, breast, and cervical cancer. Explaining details, officials said, of Tiruchy's total population of 29,29,523, 22.20 lakh adults will be screened for oral cancer, while 7.67 lakh women will be tested for breast and cervical cancer.
The targets are based on population surveys. 'Early detection saved lives in the past four years, but we've only seen the tip of the iceberg. Now, we aim to cover the entire vulnerable population,' said Dr V Thilagendran, District Programme Officer for Non-Communicable Diseases.
Adults over 18 will be screened annually for oral cancer, while women above 30 will undergo tests every three years for breast and cervical cancer. Suspected cases will be referred to government hospitals, medical colleges, and private facilities under the Chief Minister's health insurance scheme.
Screenings are available at 25 urban and 142 rural wellness centres, and 84 primary health centres,in Tiruchy. Under this scheme, women health volunteers (WHVs) will personally invite people for free checks at nearby centres. Screening camps are also planned at government offices and workplaces to ensure broad coverage.
Despite health workers delivering door-to-door invitations in pilot districts, many people did not attend the screenings, officials said. 'Early detection is possible only if people come for screening. We urge every eligible person to make use of this opportunity it could save their life,' said Dr T S Selvavinayagam, Director of Public Health.
Industries Minister T R B Rajaa inaugurated the screening camp at Mannargudi in Tiruvarur district. A total of 1,72,729 women aged 30 years and above are expected to be screened for cervical cancer, breast cancer and oral cancer. Moreover 4,71,200 men and women aged above 18 years will be screened for oral cancer. District Collector V Mohanachandran was present on the occasion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
3 hours ago
- Hans India
India's 1st animal stem cell biobank, lab to boost regenerative medicine & therapies for livestock
New Delhi: India on Saturday got the first animal stem cell biobank and animal stem cell laboratory that will focus on regenerative medicine and therapies for livestock. Inaugurated by Union Minister of State (Independent Charge) Science & Technology, Dr. Jitendra Singh, the biobank and lab is situated at the National Institute of Animal Biotechnology (NIAB), Hyderabad. The cutting-edge facility of Animal BioBank is spread over 9,300 sq ft and has been constructed at a cost of RS 1.85 crore. The laboratory is equipped with a stem cell culture unit, 3D bioprinter, bacterial culture lab, cryostorage, autoclave rooms, advanced air handling systems, and uninterrupted power backup. It will advance research in disease modelling, tissue engineering, and reproductive biotechnology. With support from the National Biopharma Mission (NBM) of DBT–BIRAC, the facility will be expanded to enable biobanking of animal stem cells and their derivatives. 'We had such facilities for human stem cells, but hardly any for animal cells. The best of NIAB, and the best of Indian biotechnology, is yet to come,' Singh said, adding that these facilities will contribute "to making India future-ready". 'We will not lag behind when the next industrial revolution—driven by biotechnology—takes over. The economy will shift from manufacturing to regenerative and genetic processes, and India has already initiated this transition,' he added. The Minister also laid the foundation stone of a new hostel block and Type-IV quarters at NIAB, approved by the Department of Biotechnology at a total cost of Rs 19.98 crore. The infrastructure will cater to the needs of research scholars, faculty, and staff, fostering a vibrant academic and innovation ecosystem. In addition, Singh launched innovative veterinary diagnostic tools designed to revolutionise animal health management and support the 'One Health' approach. These include a field-deployable, DIVA-capable diagnostic kit for early and accurate detection of Brucella species; a cost-effective on-site diagnostic assay for subclinical and clinical mastitis in dairy cattle; a portable antimicrobial sensitivity testing device providing results within two hours to promote responsible antibiotic use; a sensitive and specific test for Toxoplasma gondii infection in animals; an indigenously developed rapid strip for large-scale surveillance of Japanese Encephalitis in animals and humans. 'These innovations will boost agriculture-linked GDP, enhance livestock productivity, and pave the way for an 'Evergreen Revolution' in the animal husbandry sector,' the Minister emphasised. On the agricultural front, 'these releases mark a new phase of animal-based agricultural productivity -- an 'Evergreen Revolution'. With 18 per cent of GDP from agriculture and 60 per cent of our workforce depending on it, innovations in veterinary health will have a transformative impact,' he said. 'One rupee spent on agricultural research yields a return of Rs 13, and linking industry partners from day one ensures these technologies reach the ground,' Singh added.
Business Standard
6 hours ago
- Business Standard
Shilpa Medicare gets Shilpa Medicare approval for novel NAFLD drug NorUDCA
Shilpa Medicare has announced the receipt of approval of its, Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, by the Central Drugs Standard Control Organization (CDSCO), marking a major milestone in innovative NAFLD therapy in India. The approval reinforces Shilpa Medicares commitment to addressing unmet medical needs in hepatology through innovation and evidence‐based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD. NorUDCA is the first‐in‐class treatment for non‐alcoholic fatty liver disease (NAFLD) in India, addressing a significant unmet medical need. NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the worlds population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone. If not managed early, NAFLD may progress to non‐alcoholic steatohepatitis (NASH) and severe liver complications, underscoring the urgent necessity for effective therapy. These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCAs superior efficacy compared to placebo in NAFLD. Vishnukant Bhutada, managing director, Shilpa Medicare, said: "We are delighted to receive historic approval for NorUDCA, Indias first‐in‐class therapy for NAFLDmaking Shilpa the first company globally to obtain approval for NorUDCA in this indication. This milestone is a moment of immense pride for Shilpa and the nation, as we now pioneer the launch of its finished dosage form. This breakthrough exemplifies Shilpas unwavering dedication to innovation and accessible healthcare to millions battling liver disease in India and beyond. We are excited to introduce NorUDCA tabletsin India immediately, while advancing global regulatory efforts to bring this vital therapy to patients internationally. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24. The scrip had advanced 1.46% to end at Rs 831.80 on the BSE on Friday.
Time of India
8 hours ago
- Time of India
1,114 hospitals de-empanelled, 1,504 penalised under Ayushman Bharat Insurance scheme
New Delhi: Actions including de-empanelment of 1,114 hospitals, levying penalty worth Rs 122 crore on 1,504 errant hospitals and suspension of 549 hospitals have been taken against fraudulent entities under the Ayushman Bharat Health Insurance scheme as reported by the states and Union Territories (UTs), the Lok Sabha was told on Friday. In a written reply, Minister of State for Health and Family Welfare Prataprao Jadhav said that Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is governed on a zero-tolerance policy towards misuse and abuse. Various steps are taken for prevention, detection and deterrence of different kinds of irregularities that could occur in the scheme at different stages of its implementation, he added. A robust anti-fraud mechanism has been put in place and the National Anti-Fraud Unit (NAFU) has been set up with the primary responsibility for prevention, detection and deterrence of misuse and abuse under AB-PMJAY. "Suitable actions including de-empanelment of 1,114 hospitals, levying penalty worth Rs 122 crore on 1,504 errant hospitals and suspension of 549 hospitals have been taken against fraudulent entities as reported by the states and UTs," Jadhav said. According to the terms and conditions of empanelment, hospitals cannot deny treatment to eligible beneficiaries of the scheme. In case of denial of treatment by the empanelled hospital, beneficiaries can lodge complaints, he said. Under the AB-PMJAY, a three-tier grievance redressal system at the district, state and national level has been created to resolve the issues faced by beneficiaries in utilising healthcare services . There is a dedicated nodal officer and grievance redressal committees at each level to address the grievances. Beneficiaries can file their grievances using different mediums including web-based portal, centralised grievance redressal management system (CGRMS), central and state call centres (14555), email, letter to state health agencies (SHAs) and the like. Based on the nature of the grievance, necessary action including providing support to the beneficiaries in availing treatment under the scheme is taken, Jadhav said. Settlement of claims is an ongoing process. Under the AB-PMJAY, claims are settled by respective SHAs. The NHA has laid down guidelines for the payment of claims to hospitals within 15 days of claims submission for the intra-state hospitals (hospitals located within a state) and within 30 days in case of portability claims (hospitals located outside a state), the minister informed. Claims are required to be settled within the timeline specified under the scheme. Notable improvements have been recorded in the overall average turnaround time (TAT) for claim settlements year on year. Regular review meetings are organised to take stock of the progress with regard to the claims. Further, capacity-building activities are organised for efficient claims settlement, he said.
